Intravitreal Fluocinolone 0.19mg Implant in the Management of Chronic Non-Infectious Uveitis: 12-Month Outcomes from a Single Tertiary Centre

References

• Jones NP. Manchester uveitis clinic: the first 3000 patients: 2. Complications and management. Ocul Immunol Inflamm. April, 2015;23:127–134. doi:10.3109/09273948.2014.968671.
   PubMed Web of Science ®Google Scholar
• Lardenoye CW, Van Kooij B, Rothova A. Impact of macular edema on visual acuity in uveitis. Ophthalmology. August, 2006;113(8):1446–1449. doi:10.1016/j.ophtha.2006.03.027.
   PubMed Web of Science ®Google Scholar
• Ngyuen QD, Callanan D, Dugel P, Godfrey D, Goldstein D, Wilensky J. Treating chronic noninfectious posterior segment uveitis: the impact of cumulative damage. Proceedings of an expert panel roundtable discussion. Retina. October, 2006;Suppl:1–16. doi:10.1097/01.iae.0000250601.15893.5f.
   PubMedGoogle Scholar
• Jabs DA, Rosenbaum JT, Foster CS, et al. Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. Am J Ophthalmol. October, 2000;130(4):492–513. doi:10.1016/S0002-9394(00)00659-0.
   PubMed Web of Science ®Google Scholar
• Huscher D, Thiele K, Gromnica-Ihle E, et al. Dose-related patterns of glucocorticoid-induced side effects. Ann Rheum Dis. July, 2009;68(7):1119–1124. doi:10.1136/ard.2008.092163.
   PubMed Web of Science ®Google Scholar
• Jabs DA, Akpek EK. Immunosuppression for posterior uveitis. Retina. February, 2005;25(1):1–18. doi:10.1097/00006982-200501000-00001.
   PubMed Web of Science ®Google Scholar
• Tempest-Roe S, Joshi L, Dick AD, Taylor SR. Local therapies for inflammatory eye disease in translation: past, present and future. BMC Ophthalmol. August, 2013;13(1):39. doi:10.1186/1471-2415-13-39.
   PubMedGoogle Scholar
• Whitcup SM, Robinson MR. Development of a dexamethasone intravitreal implant for the treatment of noninfectious posterior segment uveitis. Ann N Y Acad Sci. November, 2015;1358:1–12. doi:10.1111/nyas.12824.
   PubMed Web of Science ®Google Scholar
• Zarranz-Ventura J, Carreño E, Johnston RL, et al. Multicenter study of intravitreal dexamethasone implant in noninfectious uveitis: indications, outcomes, and reinjection frequency. Am J Ophthalmol. December, 2014;158(6):1136–1145. doi:10.1016/j.ajo.2014.09.003.
   PubMed Web of Science ®Google Scholar
• Lowder C, Jr BR, Lightman S, et al. Dexamethasone intravitreal implant for noninfectious intermediate or posterior uveitis. Arch Ophthalmol. May, 2011;129(5):545–553. doi:10.1001/archophthalmol.2010.339.
   PubMed Web of Science ®Google Scholar
• Steeples LR, Anand N, Moraji J, Jones NP. Clinical outcomes of intravitreal preservative-free triamcinolone preparation (Triesence®) for cystoid macular oedema and inflammation in patients with uveitis. Ocul Immunol Inflamm. March, 2017;26:997–1004. doi:10.1080/09273948.2017.1294185.
   PubMed Web of Science ®Google Scholar
• Thorne JE, Sugar EA, Holbrook JT, et al. Periocular triamcinolone vs. intravitreal triamcinolone vs. intravitreal dexamethasone implant for the treatment of uveitic macular edema: the PeriOcular vs. INTravitreal corticosteroids for uveitic macular edema (POINT) Trial. Ophthalmology. February, 2019;126(2):283–295. doi:10.1016/j.ophtha.2018.08.021.
   PubMed Web of Science ®Google Scholar
• Cabrera M, Yeh S, Albini TA. Sustained-release corticosteroid options. J Ophthalmol Internet]. July, 2014;2014:164692. doi:10.1155/2014/164692. Accessed November 29, 2020.
   PubMed Web of Science ®Google Scholar
• Arcinue CA, Cerón OM, Foster CS. A comparison between the fluocinolone acetonide (Retisert) and dexamethasone (Ozurdex) intravitreal implants in uveitis. J Ocul Pharmacol Ther. June, 2013;29(5):501–507. doi:10.1089/jop.2012.0180.
   PubMed Web of Science ®Google Scholar
• Goldstein DA, Godfrey DG, Hall A, et al. Intraocular pressure in patients with uveitis treated with fluocinolone acetonide implants. Arch Ophthalmol. November, 2007;125(11):1478–1485.
   PubMedGoogle Scholar
• Jaffe GJ, Pavesio C; on behalf of the Study Investigators. Effect of an injectable fluocinolone acetonide insert on recurrence rates in noninfectious uveitis affecting the posterior segment: three-year results. Ophthalmology. October, 2020;127(10):1395–1404. doi:10.1016/j.ophtha.2020.04.001.
   PubMed Web of Science ®Google Scholar
• Jaffe GJ, Foster S, Pavesio C, Paggiarino D, Riedel GE. Effect of an injectable fluocinolone acetonide insert on recurrence rates in noninfectious uveitis affecting the posterior segment: 12-month results. Ophthalmology. April, 2019;126(4):601–610. doi:10.1016/j.ophtha.2018.10.033.
   PubMed Web of Science ®Google Scholar
• Campochiaro PA, Nguyen QD, Hafiz G, et al. Aqueous levels of fluocinolone acetonide after administration of fluocinolone acetonide inserts or fluocinolone acetonide implants. Ophthalmology. March, 2013;120(3):583–587. doi:10.1016/j.ophtha.2012.09.014.
   PubMed Web of Science ®Google Scholar
• Pouwels XGLV, Petersohn S, Carrera VH, et al. Fluocinolone acetonide intravitreal implant for treating recurrent non-infectious uveitis: an evidence review group perspective of a NICE single technology appraisal. Pharmacoeconomics. 2020;38(5):431–441. doi:10.1007/s40273-019-00851-z.
   PubMed Web of Science ®Google Scholar
• NICE. Fluocinolone acetonide intravitreal implant for treating recurrent noninfectious uveitis. Technology appraisal guidance [Internet]. United Kingdom: NICE. https://www.nice.org.uk/guidance/ta590. 2019. Accessed November 29, 2020.
   Google Scholar
• Lange C, Feltgen N, Junker B, Schulze-Bonsel K, Bach M. Resolving the clinical acuity categories “hand motion” and “counting fingers” using the freiburg visual acuity test (FrACT). Graefes Arch Clin Exp Ophthalmol. 2009;247(1):137–142. doi:10.1007/s00417-008-0926-0.
   PubMed Web of Science ®Google Scholar
• Nussenblatt RB, Palestine AG, Chan CC, Roberge F. Standardization of vitreal inflammatory activity in intermediate and posterior uveitis. Ophthalmology. April, 1985;92(4):467–471. doi:10.1016/S0161-6420(85)34001-0.
   PubMed Web of Science ®Google Scholar
• Weber LF, Marx S, Auffarth GU, et al. Injectable 0.19-mg fluocinolone acetonide intravitreal implant for the treatment of non-infectious uveitic macular edema. J Ophthalmic Inflamm Infect. 2019;9:3. doi:10.1186/s12348-019-0168-9.
   PubMed Web of Science ®Google Scholar
• Friedman DS, Holbrook JT, Ansari H, et al. Risk of elevated intraocular pressure and glaucoma in patients with uveitis; results of the multicenter uveitis steroid treatment trial. Ophthalmology. August, 2013;120(8):1571–1579. doi:10.1016/j.ophtha.2013.01.025.
   PubMed Web of Science ®Google Scholar